Drug Profile

Metformin controlled release - Avadel Pharmaceuticals

Alternative Names: Metformin XL

Latest Information Update: 17 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Flamel Technologies
Class Antihyperglycaemics; Biguanides; Eye disorder therapies; Small molecules
Mechanism of Action AMP activated protein kinase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

No development reported Type 2 diabetes mellitus

Most Recent Events

12 Feb 2026 Avadel Pharmaceuticals has been acquired by Alkermes plc
16 Sep 2015 No recent reports on development identified - Phase-II for Type-2 diabetes mellitus in France (PO)
23 Oct 2012 Metformin controlled release - Flamel Technologies is still available for licensing http://www/flamel.com

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com